In vivo effect of pneumonia on surfactant disaturated-phosphatidylcholine kinetics in newborn infants

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Facco, Maddalena ^a   Nespeca, Matteo ^b   Simonato, Manuela ^a   Isak, Ilena ^a   Verlato, Giovanna ^a   Ciambra, Gianluca ^b   Giorgetti, Chiara ^b   Carnielli, Virgilio P ^b   Cogo, Paola E ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISATURATED PHOSPHATIDYLCHOLINE; LUNG SURFACTANT; MYELOPEROXIDASE; PHOSPHATIDYLCHOLINE; PORACTANT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; LECITHINS, DISATURATED; PEROXIDASE;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; ENZYME ACTIVITY; EPITHELIAL LINING FLUID; GESTATIONAL AGE; HALF LIFE TIME; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MASS FRAGMENTOGRAPHY; NEWBORN; NEWBORN INFECTION; PNEUMONIA; PROSPECTIVE STUDY; RESPIRATORY FAILURE; TRACHEAL ASPIRATION PROCEDURE; CASE CONTROL STUDY; FEMALE; LUNG; MALE; METABOLISM; PREMATURITY;

BACTERIA (MICROORGANISMS);

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; CASE-CONTROL STUDIES; DIAGNOSTIC USES OF CHEMICALS; FEMALE; GESTATIONAL AGE; HALF-LIFE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LUNG; MALE; PEROXIDASE; PHOSPHATIDYLCHOLINES; PNEUMONIA; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL;

EID: 84938630378     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093612     Document Type: Article

References (39)

1. Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer F (2008) Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochimica et biophysica acta 1778: 1947-1977.
2. Rudiger M, Friedrich W, Rustow B, Schmalisch G, Wauer R (2001) Disturbed surface properties in preterm infants with pneumonia. Biology of the neonate 79: 73-78.
3. Malloy JL, Wright JR (2004) In vivo clearance of surfactant lipids during acute pulmonary inflammation. Respiratory research 5: 8.
4. Song GW, Robertson B, Curstedt T, Gan XZ, Huang WX (1996) Surfactant treatment in experimental Escherichia coli pneumonia. Acta anaesthesiologica Scandinavica 40: 1154-1160.
5. Stichtenoth G, Linderholm B, Bjorkman MH, Walter G, Curstedt T, et al. (2010) Prophylactic intratracheal polymyxin B/surfactant prevents bacterial growth in neonatal Escherichia coli pneumonia of rabbits. Pediatric research 67: 369-374.
6. Herting E, Gan X, Rauprich P, Jarstrand C, Robertson B (1999) Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. American journal of respiratory and critical care medicine 159: 1862-1867.
7. Harms K, Herting E (1994) Successful surfactant replacement therapy in two infants with ARDS due to chlamydial pneumonia. Respiration; international review of thoracic diseases 61: 348-352.
8. Herting E, Moller O, Schiffmann JH, Robertson B (2002) Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome. Acta Paediatr 91: 1174-1178.
9. Gortner L, Pohlandt F, Bartmann P (1990) [Effect of a bovine surfactant in very low birth weight premature infants with congenital pneumonia]. Monatsschrift Kinderheilkunde: Organ der Deutschen Gesellschaft fur Kinderheilkunde 138: 274-278.
10. Herting E, Gefeller O, Land M, van Sonderen L, Harms K, et al. (2000) Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 106: 957-964; discussion 1135.
11. Soll RF (2009) Current trials in the treatment of respiratory failure in preterm infants. Neonatology 95: 368-372.
12. Seger N, Soll R (2009) Animal derived surfactant extract for treatment of respiratory distress syndrome. The Cochrane database of systematic reviews: CD007836.
13. El Shahed AI, Dargaville P, Ohlsson A, Soll RF (2007) Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane database of systematic reviews: CD002054.
14. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, et al. (1998) Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. The Journal of pediatrics 132: 40-47.
15. Dargaville PA, Mills JF (2005) Surfactant therapy for meconium aspiration syndrome: current status. Drugs 65: 2569-2591.
16. Tan K, Lai NM, Sharma A (2012) Surfactant for bacterial pneumonia in late preterm and term infants. Cochrane Database Syst Rev 2: CD008155.
17. Cogo PE, Carnielli VP, Bunt JE, Badon T, Giordano G, et al. (1999) Endogenous surfactant metabolism in critically ill infants measured with stable isotope labeled fatty acids. Pediatric research 45: 242-246.
18. Cogo PE, Simonato M, Mariatoffolo G, Stefanutti G, Chierici M, et al. (2008) Dexamethasone therapy in preterm infants developing bronchopulmonary dysplasia: effect on pulmonary surfactant disaturated-phosphatidylcholine kinetics. Pediatric research 63: 433-437.
19. Verlato G, Cogo PE, Pesavento R, Gomirato S, Benetazzo A, et al. (2003) Surfactant kinetics in newborn infants with pneumonia and Respiratory Distress Syndrome. Italian Journal of Pediatrics 29: 414-419.
20. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American journal of infection control 36: 309-332.
21. Torresin M, Zimmermann LJ, Cogo PE, Cavicchioli P, Badon T, et al. (2000) Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes. Am J Respir Crit Care Med 161: 1584-1589.
22. Cogo PE, Zimmermann LJ, Pesavento R, Sacchetto E, Burighel A, et al. (2003) Surfactant kinetics in preterm infants on mechanical ventilation who did and did not develop bronchopulmonary dysplasia. Crit Care Med 31: 1532-1538.
23. Cogo PE, Toffolo GM, Ori C, Vianello A, Chierici M, et al. (2007) Surfactant disaturated-phosphatidylcholine kinetics in acute respiratory distress syndrome by stable isotopes and a two compartment model. Respiratory research 8: 13.
24. Cogo PE, Facco M, Simonato M, De Luca D, De Terlizi F, et al. (2011) Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome. Intensive care medicine 37: 510-517.
25. Cogo PE, Facco M, Simonato M, Verlato G, Rondina C, et al. (2009) Dosing of porcine surfactant: effect on kinetics and gas exchange in respiratory distress syndrome. Pediatrics 124: e950-957.
26. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Canadian journal of biochemistry and physiology 37: 911-917.
27. Touchstone JCC, J. C.; Beaver, M. K. (1980) Improved separation of phospholipids in thin layer chromatography. Lipids 15: 61-62.
28. Dargaville PA, South M, Vervaart P, McDougall PN (1999) Validity of markers of dilution in small volume lung lavage. American journal of respiratory and critical care medicine 160: 778-784.
29. Brehmer U, Jorch G (1993) [Surfactant therapy in severe neonatal respiratory failure - multicenter study - III. Surfactant therapy in 41 premature infants < 34 weeks with suspected congenital infection (case-control analysis)]. Klinische Padiatrie 205: 78-82.
30. Hallman M, Merritt TA, Pohjavuori M, Gluck L (1986) Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. Pediatric research 20: 1228-1235.
31. Griese M, Dietrich P, Reinhardt D (1995) Pharmacokinetics of bovine surfactant in neonatal respiratory distress syndrome. American journal of respiratory and critical care medicine 152: 1050-1054.
32. Bauer TT, Ewig S, Rodloff AC, Muller EE (2006) Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 43: 748-756.
33. Quintero OA, Wright JR (2002) Clearance of surfactant lipids by neutrophils and macrophages isolated from the acutely inflamed lung. American journal of physiology Lung cellular and molecular physiology 282: L330-339.
34. Ikegami M (2006) Surfactant catabolism. Respirology 11 Suppl: S24-27.
35. Hilgendorff A, Aslan E, Schaible T, Gortner L, Baehner T, et al. (2008) Surfactant replacement and open lung concept - comparison of two treatment strategies in an experimental model of neonatal ARDS. BMC pulmonary medicine 8: 10.
36. van Kaam AH, de Jaegere A, Haitsma JJ, Van Aalderen WM, Kok JH, et al. (2003) Positive pressure ventilation with the open lung concept optimizes gas exchange and reduces ventilator-induced lung injury in newborn piglets. Pediatric research 53: 245-253.
37. van Kaam AH, Dik WA, Haitsma JJ, De Jaegere A, Naber BA, et al. (2003) Application of the open-lung concept during positive-pressure ventilation reduces pulmonary inflammation in newborn piglets. Biology of the neonate 83: 273-280.
38. Plataki M, Hubmayr RD (2010) The physical basis of ventilator-induced lung injury. Expert review of respiratory medicine 4: 373-385.
39. Halbertsma FJ, Vaneker M, Scheffer GJ, van der Hoeven JG (2005) Cytokines and biotrauma in ventilator-induced lung injury: a critical review of the literature. The Netherlands journal of medicine 63: 382-392.